The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been approved for the treatment of hormone receptor-positive breast cancer. In this study, we use murine syngeneic tumor models and in vitro assays to investigate the impact of abemaciclib on T cells, the t...

Full description

Bibliographic Details
Main Authors: David A. Schaer, Richard P. Beckmann, Jack A. Dempsey, Lysiane Huber, Amelie Forest, Nelusha Amaladas, Yanxia Li, Ying Cindy Wang, Erik R. Rasmussen, Darin Chin, Andrew Capen, Carmine Carpenito, Kirk A. Staschke, Linda A. Chung, Lacey M. Litchfield, Farhana F. Merzoug, Xueqian Gong, Philip W. Iversen, Sean Buchanan, Alfonso de Dios, Ruslan D. Novosiadly, Michael Kalos
Format: Article
Language:English
Published: Elsevier 2018-03-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124718302341

Internet

http://www.sciencedirect.com/science/article/pii/S2211124718302341

Similar Items